{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T20:21:18Z","timestamp":1786393278058,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s13760-024-02555-4","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T01:01:40Z","timestamp":1718067700000},"page":"1847-1854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rituximab maintenance treatment outcomes in patients with relapsing neuromyelitis optica spectrum disorder: a monocentric retrospective analysis"],"prefix":"10.1007","volume":"124","author":[{"given":"Lianchen","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-2630","authenticated-orcid":false,"given":"Lei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"2555_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3988\/jcn.2022.18.2.152","volume":"18","author":"MV Jeyalatha","year":"2022","unstructured":"Jeyalatha MV, Therese KL, Anand AR (2022) An update on the laboratory diagnosis of neuromyelitis optica spectrum disorders. J Clin Neurol 18:152\u2013162. https:\/\/doi.org\/10.3988\/jcn.2022.18.2.152","journal-title":"J Clin Neurol"},{"key":"2555_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B (2020) Neuromyelitis optica. Nat Rev Dis Primers 6:85. https:\/\/doi.org\/10.1038\/s41572-020-0214-9","journal-title":"Nat Rev Dis Primers"},{"key":"2555_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12974-022-02623-7","volume":"19","author":"Y Morita","year":"2022","unstructured":"Morita Y, Itokazu T, Nakanishi T, Hiraga SI, Yamashita T (2022) A novel aquaporin-4-associated optic neuritis rat model with severe pathological and functional manifestations. J Neuroinflammation 19:263. https:\/\/doi.org\/10.1186\/s12974-022-02623-7","journal-title":"J Neuroinflammation"},{"key":"2555_CR4","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","volume":"142","author":"J Palace","year":"2019","unstructured":"Palace J, Lin DY, Zeng D, Majed M, Elsone L, Hamid S, Messina S, Misu T, Sagen J, Whittam D, Takai Y, Leite MI, Weinshenker B, Cabre P, Jacob A, Nakashima I, Fujihara K, Pittock SJ (2019) Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain 142:1310\u20131323. https:\/\/doi.org\/10.1093\/brain\/awz054","journal-title":"Brain"},{"key":"2555_CR5","doi-asserted-by":"publisher","first-page":"102522","DOI":"10.1016\/j.msard.2020.102522","volume":"46","author":"X Ma","year":"2020","unstructured":"Ma X, Kermode AG, Hu X, Qiu W (2020) Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy. Mult Scler Relat Disord 46:102522. https:\/\/doi.org\/10.1016\/j.msard.2020.102522","journal-title":"Mult Scler Relat Disord"},{"key":"2555_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/wnl.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 53:1107\u20131114. https:\/\/doi.org\/10.1212\/wnl.53.5.1107","journal-title":"Neurology"},{"key":"2555_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","volume":"96","author":"V Papp","year":"2021","unstructured":"Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P, Jacob A, Kira JI, Leite MI, Marignier R, Miyamoto K, Palace J, Saiz A, Sepulveda M, Sveinsson O, Illes Z (2021) Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology 96:59\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000011153","journal-title":"Neurology"},{"key":"2555_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H (2020) Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19:298\u2013306. https:\/\/doi.org\/10.1016\/S1474-4422(20)30066-1","journal-title":"Lancet Neurol"},{"key":"2555_CR9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/1352458515594042","volume":"22","author":"M Radaelli","year":"2016","unstructured":"Radaelli M, Moiola L, Sangalli F, Esposito F, Barcella V, Ferr\u00e8 L, Rodegher M, Colombo B, Fazio R, Martinelli V, Comi G (2016) Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler 22:511\u2013519. https:\/\/doi.org\/10.1177\/1352458515594042","journal-title":"Mult Scler"},{"key":"2555_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4103\/ijmr.IJMR_312_19","volume":"155","author":"F Saffari","year":"2022","unstructured":"Saffari F, Jafarzadeh A (2022) Development of anti-rituximab antibodies in rituximab-treated patients: related parameters & consequences. Indian J Med Res 155:335\u2013346. https:\/\/doi.org\/10.4103\/ijmr.IJMR_312_19","journal-title":"Indian J Med Res"},{"key":"2555_CR11","doi-asserted-by":"publisher","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","volume":"94","author":"J Poupart","year":"2020","unstructured":"Poupart J, Giovannelli J, Deschamps R, Audoin B, Ciron J, Maillart E, Papeix C, Collongues N, Bourre B, Cohen M, Wiertlewski S, Outteryck O, Laplaud D, Vukusic S, Marignier R, Zephir H, NOMADMUS study group (2020) Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology 94:e1645\u2013e1656. https:\/\/doi.org\/10.1212\/WNL.0000000000009245","journal-title":"Neurology"},{"key":"2555_CR12","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70:1110\u20131117. https:\/\/doi.org\/10.1001\/jamaneurol.2013.3071","journal-title":"JAMA Neurol"},{"key":"2555_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMO Diagnosis (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"issue":"Pt 6","key":"2555_CR14","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, Takai Y, Takahashi T, Misu T, Elsone L, Woodhall M, George J, Boggild M, Vincent A, Jacob A, Fujihara K, Palace J (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain\u202f: J Neurol 135(Pt 6):1834\u20131849. https:\/\/doi.org\/10.1093\/brain\/aws109","journal-title":"Brain : J Neurol"},{"issue":"9","key":"2555_CR15","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F (2017) Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 264(9):2003\u20132009. https:\/\/doi.org\/10.1007\/s00415-017-8590-0","journal-title":"J Neurol"},{"issue":"8","key":"2555_CR16","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1111\/ene.15355","volume":"29","author":"W Huang","year":"2022","unstructured":"Huang W, Wang L, Xia J, Li W, Wang M, Yu J, Li Q, Wang B, Pan J, Du L, Ma J, Tan H, Chang X, Lu C, Zhao C, Lu J, Zhou L, ZhangBao J, Quan C, Pan-Yangtze River Delta Alliance for Demyelinating Disease (2022) Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder. Eur J Neurol 29(8):2343\u20132354. https:\/\/doi.org\/10.1111\/ene.15355","journal-title":"Eur J Neurol"},{"issue":"1","key":"2555_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, H\u00e4u\u00dfler V, Havla J, Hellwig K, H\u00fcmmert MW, Jarius S, Kleiter I, Klotz L, Krumbholz M, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Trebst C, Neuromyelitis Optica Study Group (NEMOS) (2024) Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS) Part II attack therapy and long-term management. J Neurol 271(1):141\u2013176. https:\/\/doi.org\/10.1007\/s00415-023-11910-z","journal-title":"J Neurol"},{"issue":"4","key":"2555_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H (2020) Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet Neurol 19(4):298\u2013306. https:\/\/doi.org\/10.1016\/S1474-4422(20)30066-1","journal-title":"The Lancet Neurol"},{"issue":"6","key":"2555_CR19","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/annonc\/mdf155","volume":"13","author":"T Igarashi","year":"2002","unstructured":"Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, Morishima Y, Murate T, Kasai M, Uike N, Taniwaki M, Kano Y, Ohnishi K, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K, IDEC-C2B8 Study Group in Japan (2002) Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Annals Oncol\u202f: Off J Eur Soc Med Oncol 13(6):928\u2013943. https:\/\/doi.org\/10.1093\/annonc\/mdf155","journal-title":"Annals Oncol : Off J Eur Soc Med Oncol"},{"key":"2555_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.004","volume":"317","author":"J Lin","year":"2018","unstructured":"Lin J, Li X, Xue B, Tong Q, Chen Z, Zhu W, Li J, Xia J (2018) Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder. J Neuroimmunol 317:1\u20134. https:\/\/doi.org\/10.1016\/j.jneuroim.2018.02.004","journal-title":"J Neuroimmunol"},{"key":"2555_CR21","doi-asserted-by":"publisher","first-page":"103143","DOI":"10.1016\/j.msard.2021.103143","volume":"54","author":"B Shi","year":"2021","unstructured":"Shi B, Zhao M, Qiao L, Huang F, Zhou S, Wei Y, Wang J, Wang N (2021) Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 54:103143. https:\/\/doi.org\/10.1016\/j.msard.2021.103143","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"2555_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/1352458515594042","volume":"22","author":"M Radaelli","year":"2016","unstructured":"Radaelli M, Moiola L, Sangalli F, Esposito F, Barcella V, Ferr\u00e8 L, Rodegher M, Colombo B, Fazio R, Martinelli V, Comi G (2016) Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler (Houndmills, Basingstoke, England) 22(4):511\u2013519. https:\/\/doi.org\/10.1177\/1352458515594042","journal-title":"Mult Scler (Houndmills, Basingstoke, England)"},{"key":"2555_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","volume":"373","author":"M Cohen","year":"2017","unstructured":"Cohen M, Romero G, Bas J, Ticchioni M, Rosenthal M, Lacroix R, Brunet C, Rico A, Pelletier J, Audoin B, Lebrun C (2017) Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study. J Neurol Sci 373:335\u2013338. https:\/\/doi.org\/10.1016\/j.jns.2017.01.025","journal-title":"J Neurol Sci"},{"issue":"2","key":"2555_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40120-018-0101-4","volume":"7","author":"C Lebrun","year":"2018","unstructured":"Lebrun C, Cohen M, Rosenthal-Allieri MA, Bresch S, Benzaken S, Marignier R, Seitz-Polski B, Ticchioni M (2018) Only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders. Neurol Ther 7(2):373\u2013383. https:\/\/doi.org\/10.1007\/s40120-018-0101-4","journal-title":"Neurol Ther"},{"key":"2555_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.nrl.2014.09.001","volume":"30","author":"MJ Fern\u00e1ndez-Meg\u00eda","year":"2015","unstructured":"Fern\u00e1ndez-Meg\u00eda MJ, Casanova-Estruch B, P\u00e9rez-Miralles F, Ruiz-Ramos J, Alcal\u00e1-Vicente C, Poveda-Andr\u00e9s JL (2015) Clinical evaluation of rituximab treatment for neuromyelitis optica. Neurologia 30:461\u2013464. https:\/\/doi.org\/10.1016\/j.nrl.2014.09.001","journal-title":"Neurologia"},{"key":"2555_CR26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","volume":"81","author":"CS Yang","year":"2013","unstructured":"Yang CS, Yang L, Li T, Zhang DQ, Jin WN, Li MS, Su N, Zhangning N, Liu Q, Shao ZH, Yu C, Shi FD (2013) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81:710\u2013713. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a1aac7","journal-title":"Neurology"},{"key":"2555_CR27","doi-asserted-by":"publisher","first-page":"175628641987118","DOI":"10.1177\/1756286419871187","volume":"12","author":"K Choi","year":"2019","unstructured":"Choi K, Hong YH, Ahn SH, Baek SH, Kim JS, Shin JY, Sung JJ (2019) Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis. Ther Adv Neurol Disord 12:1756286419871187. https:\/\/doi.org\/10.1177\/1756286419871187","journal-title":"Ther Adv Neurol Disord"},{"key":"2555_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.22088\/cjim.11.2.155","volume":"11","author":"M Seyed Ahadi","year":"2020","unstructured":"Seyed Ahadi M, Naser Moghadasi A, Asgari N, Sahraian MA (2020) Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: a prospective observation in Iranian cases. Caspian J Intern Med 11:155\u2013162. https:\/\/doi.org\/10.22088\/cjim.11.2.155","journal-title":"Caspian J Intern Med"},{"key":"2555_CR29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/ICU.0000000000000202","volume":"26","author":"I Vodopivec","year":"2015","unstructured":"Vodopivec I, Matiello M, Prasad S (2015) Treatment of neuromyelitis optica. Curr Opin Ophthalmol 26:476\u2013483. https:\/\/doi.org\/10.1097\/ICU.0000000000000202","journal-title":"Curr Opin Ophthalmol"},{"key":"2555_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1586\/14737175.2016.1150178","volume":"16","author":"J Kitley","year":"2016","unstructured":"Kitley J, Palace J (2016) Therapeutic options in neuromyelitis optica spectrum disorders. Expert Rev Neurother 16:319\u2013329. https:\/\/doi.org\/10.1586\/14737175.2016.1150178","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"2555_CR31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ana.25648","volume":"87","author":"P Durozard","year":"2020","unstructured":"Durozard P, Rico A, Boutiere C, Maarouf A, Lacroix R, Cointe S, Fritz S, Brunet C, Pelletier J, Marignier R, Audoin B (2020) Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol 87(2):256\u2013266. https:\/\/doi.org\/10.1002\/ana.25648","journal-title":"Ann Neurol"},{"key":"2555_CR32","doi-asserted-by":"publisher","first-page":"103926","DOI":"10.1016\/j.msard.2022.103926","volume":"63","author":"G Abbadessa","year":"2022","unstructured":"Abbadessa G, Miele G, Maida E, Minervini G, Lavorgna L, Bonavita S (2022) Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: a systematic review. Multiple sclerosis and related disorders 63:103926. https:\/\/doi.org\/10.1016\/j.msard.2022.103926","journal-title":"Multiple sclerosis and related disorders"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02555-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02555-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02555-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T02:05:46Z","timestamp":1733277946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02555-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2555"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02555-4","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"15 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The data that support the findings of this study are available on request from the corresponding author, L. W and D. H, on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}